US Broker Ratings

Addus HomeCare Corporation (ADUS) Stock Analysis: Exploring a 27% Upside Potential

Addus HomeCare Corporation (NASDAQ: ADUS) is garnering attention within the healthcare sector, primarily due to its robust growth trajectory and promising upside potential reflected in recent analyst ratings. As a..

MoonLake Immunotherapeutics (MLTX) Stock Analysis: A Biotech Contender with 36% Upside Potential

MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology firm based in Zug, Switzerland, is making waves in the healthcare sector with its innovative approach to treating inflammatory skin and joint diseases. Specializing..

Denali Therapeutics Inc. (DNLI) Stock Analysis: Unpacking the 102.56% Potential Upside

Denali Therapeutics Inc. (NASDAQ: DNLI) stands at the forefront of biopharmaceutical innovation, developing groundbreaking therapeutics for neurodegenerative and lysosomal storage diseases. With a market capitalization of $2.29 billion, this South..

QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 90% Upside Potential

QuidelOrtho Corporation (NASDAQ: QDEL) stands out in the healthcare sector with its focus on medical devices, providing a robust range of diagnostic testing solutions. Headquartered in San Diego, California, this..

Sotera Health Company (SHC) Stock Analysis: Exploring a 20% Potential Upside in the Healthcare Sector

Sotera Health Company (NASDAQ: SHC) stands as a formidable entity within the healthcare sector, specifically in the diagnostics and research industry. With a market capitalization of $4.47 billion, Sotera provides..

Crinetics Pharmaceuticals (CRNX) Stock Analysis: Exploring an 88.98% Potential Upside in the Biotech Sphere

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is making waves in the biotechnology sector with its innovative approach to tackling rare endocrine diseases and endocrine-related tumors. The company, headquartered in San Diego,..

Catalyst Pharmaceuticals (CPRX) Stock Analysis: Unpacking a 61.68% Upside Potential

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company that is making waves in the healthcare sector with its focus on rare diseases. With a market capitalization of $2.65..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring Its 7.86% Upside Potential Amid Clinical Advancements

Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a notable player in the biotechnology sector, is drawing attention with its robust market presence and promising pipeline of drug candidates. With a market capitalization..

Immunovant, Inc. (IMVT) Stock Analysis: A Promising 64.60% Upside Potential in the Biotech Sector

Immunovant, Inc. (NASDAQ: IMVT) is capturing investor attention with a compelling potential upside of 64.60%, according to recent analyst ratings. This clinical-stage biopharmaceutical company, based in New York, focuses on..

Scholar Rock Holding Corporation (SRRK) Investor Outlook: Unpacking a 58.48% Potential Upside

Scholar Rock Holding Corporation (NASDAQ: SRRK) has piqued the interest of investors with its promising biotechnology advancements and a striking 58.48% potential stock price upside. Specializing in the discovery and..

ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: A 31% Potential Upside in the Biotech Sector

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stands out in the biotechnology sector, particularly for individual investors seeking opportunities within the healthcare market. With its focus on developing treatments for central nervous..

Xenon Pharmaceuticals (XENE): Analyst Consensus Sees 43% Upside in Biotech Innovator

Investors seeking opportunities in the burgeoning biotechnology sector may find Xenon Pharmaceuticals Inc. (NASDAQ: XENE) an intriguing prospect. With a market capitalization of $2.97 billion, this Canadian biotech company is..

Surgery Partners, Inc. (SGRY) Investor Outlook: Analyzing a 78.59% Potential Upside in the Healthcare Sector

In the dynamic landscape of healthcare investments, Surgery Partners, Inc. (NASDAQ: SGRY) stands out with its intriguing potential for growth and an impressive 78.59% potential upside according to analyst ratings...

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring Growth Potential Amid Metabolic Innovations

As Akero Therapeutics, Inc. (NASDAQ: AKRO) continues its pioneering work in the biotechnology sector, investors are keenly eyeing the company’s strategic positioning in the healthcare industry. With a market capitalization..

Krystal Biotech, Inc. (KRYS) Stock Report: Navigating Growth with a Potential 10.9% Upside

Krystal Biotech, Inc. (NASDAQ: KRYS), a prominent player in the biotechnology sector, is capturing investor attention with its promising pipeline and a notable potential upside of 10.9%. With a market..

Cytokinetics (CYTK) Stock Analysis: Investors Eye 29.93% Upside on Biotech’s Promising Pipeline

Cytokinetics, Incorporated (NASDAQ: CYTK), a biopharmaceutical company focused on addressing muscle diseases, has continued to capture investor attention with its robust pipeline of drug candidates targeting debilitating conditions. With a..

Vaxcyte, Inc. (PCVX) Stock Analysis: Strong Upside Potential of 135% Amid Promising Vaccine Innovations

Vaxcyte, Inc. (NASDAQ: PCVX) is capturing the attention of investors with its promising pipeline of vaccines aimed at combating bacterial infectious diseases. As a clinical-stage biotechnology company, Vaxcyte stands out..

Axsome Therapeutics, Inc. (AXSM) Investor Outlook: Analyzing a 31% Upside Potential in the Biotech Sector

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a prominent player in the biotechnology sector, is capturing investor attention with its robust pipeline of therapies targeting central nervous system (CNS) disorders. With a..

Soleno Therapeutics, Inc. (SLNO) Investor Outlook: Exploring a Potential 147.73% Upside

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is making waves in the biotechnology sector with its focus on developing novel treatments for rare diseases. With a market capitalization of $2.56 billion, this..

TG Therapeutics, Inc. (TGTX) Stock Analysis: 37% Potential Upside Draws Investor Attention

TG Therapeutics, Inc. (NASDAQ: TGTX), with a market capitalization of $5.12 billion, is making waves in the biotechnology sector, particularly for its focus on innovative treatments for B-cell mediated diseases...

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds